Dermatology
InnoCare shares results from phase 2 trial for atopic dermatitis treatment
December 18, 2023Research and Development Dermatology, InnoCare, atopic dermatitis, clinical trial
InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients …
FDA accepts Sun Pharma’s NDA for deuruxolitinib
October 6, 2023Medical Communications Dermatology, FDA, NDA, SUun Pharma, deuruxolitinib
India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted its New …
EC approves Pfizer’s Litfulo for adolescents and adults with alopecia
September 19, 2023Medical Communications Dermatology, EC, Litfulo, alopecia
Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …
LEO Pharma to acquire Timber Pharmaceuticals for up to $36m
August 22, 2023Business Services Dermatology, LEO Pharma, Timber Pharmaceuticals, acquisition
Timber Pharmaceuticals has announced that it has entered a definitive agreement to be acquired by LEO Pharma, with a total …
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis
May 3, 2023Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab
Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
April 27, 2023Business Services CHMP, Cosentyx, Dermatology, Novartis
Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) publish Ph3 data evaluating lebrikizumab efficacy and safety in moderate-to-severe atopic dermatitis
March 31, 2023Business Services Almirall, Dermatology, dermatology, lebrikizumab
BARCELONA, Spain. March 31, 2023 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, announced today the …
